共 50 条
- [21] Adverse Events Associated with Belimumab Use in Pediatric Patients: Review and Analyses of the FDA Adverse Event Reporting System DatabaseARTHRITIS & RHEUMATOLOGY, 2022, 74 : 2683 - 2684Kim, IvoneRyan, DebraCheng, CarmenKortepeter, Cindy
- [22] Spontaneous reporting of rare events associated with atypical antipsychotics using the FDA adverse event reporting systemPHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2019, 28 : 345 - 346Emechebe, NnadozieMukhtar, FahadScheer, DarrenPatel, ArshiyaWadhawan, AbhishekSchwartz, SkaiZgibor, Janice
- [23] Immune-related adverse events for different age groups using the FDA Adverse Event Reporting System.JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)Myint, ZinQasrawi, AymanO'Neal, RichardThomas, Chris Z.Arnold, Susanne M.Wang, Peng
- [24] Unveiling the safety profile of lecanemab: A comprehensive analysis of adverse events using FDA adverse event reporting system dataJOURNAL OF ALZHEIMERS DISEASE, 2025, 103 (03) : 844 - 855Ge, WukunYan, YingyanHu, YaoyaoLin, ShuainanMao, Peizhi
- [25] Triptans and serious adverse vascular events: Data mining of the FDA Adverse Event Reporting System databaseCEPHALALGIA, 2014, 34 (01) : 5 - 13Roberto, GiuseppePiccinni, CarloD'Alessandro, RobertoPoluzzi, Elisabetta
- [26] Adverse events with risankizumab in the real world: postmarketing pharmacovigilance assessment of the FDA adverse event reporting systemFRONTIERS IN IMMUNOLOGY, 2023, 14Shu, YaminChen, JingDing, YilingZhang, Qilin
- [27] Cardiovascular adverse events associated with parp inhibitors: A disproportionality analysis of FDA adverse event reporting systemPHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2022, 31 : 452 - 452Viswam, Subeesh KulangaraKheterpal, AarushiDhas, AshwinZeba, ZebaShettigar, AmruthaLukose, LipinKaur, Gursimran
- [28] Gastrointestinal adverse events associated with semaglutide: A pharmacovigilance study based on FDA adverse event reporting systemFRONTIERS IN PUBLIC HEALTH, 2022, 10Shu, YaminHe, XuchengWu, PanLiu, YanxinDing, YufengZhang, Qilin
- [29] Novel Adverse Events of Bevacizumab in the US FDA Adverse Event Reporting System Database A Disproportionality AnalysisDRUG SAFETY, 2012, 35 (06) : 507 - 518Shamloo, Behrooz K.Chhabra, PankdeepFreedman, Andrew N.Potosky, ArnoldMalin, JenniferSmith, Sheila Weiss
- [30] Pharmacovigilance analysis of orlistat adverse events based on the FDA adverse event reporting system (FAERS) databaseHELIYON, 2024, 10 (14)Zhu, JinfengHu, MiandaLiang, YingshiZhong, MingjunChen, ZilinWang, ZhenjieYang, YujiaLuo, ZiyiZeng, WenqiLi, JiahuiDu, YikuanLiu, YiYang, Chun